Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia (HALO)

This study has been completed.

Sponsor:

Information provided by:

AstraZeneca

ClinicalTrials.gov Identifier:

NCT00528905

First received: September 10, 2007

Last updated: November 21, 2008

Last verified: November 2008

History of Changes

Purpose

The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with stable schizophrenia who are being treated with an atypical antipsychotic and who are active cigarette smokers, to assess the safety and tolerability of AZD3480 and to define the optimal dose(s) to be used in future trials.

Condition	Intervention	Phase
Schizophrenia	Drug: AZD3480	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Multi-Center Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase IIb Proof of Concept Study With 3 Oral Groups of AZD3480 During 12 Weeks Treatment of Cognitive Deficits in Patients With Schizophrenia

Resource links provided by NLM:

Genetics Home Reference related topics: schizophrenia

MedlinePlus related topics: Schizophrenia

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Domain scores for Attention/Vigilance, Working Memory, Verbal Learning, Speed of Processing and Verbal Fluency as measured on the IntegNeuro computerized test battery of cognitive function [ Time Frame: Change from baseline to Week 12 ]

Secondary Outcome Measures:

UCSD Performance Based Skills Assessment (UPSA2) and on the Social Functioning Scale (SFS) [ Time Frame: Change from baseline to Week 12 ]


Estimated Enrollment:	400
Study Start Date:	August 2007
Study Completion Date:	November 2008
Primary Completion Date:	October 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: 1 Placebo	Drug: AZD3480 oral capsule
Experimental: 2 AZD3480 oral	Drug: AZD3480 oral capsule
Experimental: 3 AZD3480 oral dose	Drug: AZD3480 oral capsule

Eligibility


Ages Eligible for Study:	18 Years to 55 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of schizophrenia
Outpatient at the time of screening and randomization
Stable housing defined as having a place to live in the community (ie, not in a hospital or nursing home)
Active cigarette smoking (10 or more cigarettes per day

Exclusion Criteria:

Any significant psychiatric or neurological disease other than schizophrenia, or current diagnosis of major depressive disorder
Known or suspected drug or alcohol abuse within the 6 months or urine toxicology test positive for illegal or non-prescribed substances
Impaired vision and/or hearing making cognitive testing difficult

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00528905

Show 80 Study Locations

Sponsors and Collaborators

AstraZeneca

Investigators


Study Director:	Larry Rodichok, MD	AstraZeneca

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site


ClinicalTrials.gov Identifier:	NCT00528905 History of Changes
Other Study ID Numbers:	D3690C00011
Study First Received:	September 10, 2007
Last Updated:	November 21, 2008

Keywords provided by AstraZeneca:


Schizophrenia Cognitive Deficits

Additional relevant MeSH terms:


Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders

ClinicalTrials.gov processed this record on July 24, 2017

To Top